Bora Lim, MD
Open to Accrual
Breast [BR]
Breast
II
No
Cohort 1: To determine whether the combination of fulvestrant and binimetinib improves PFS compared to treatment with fulvestrant alone inpatients not previously treated with fulvestrant.
Cohort 2: To determine whether ORR within 4 months in patients who have previously progressed on a fulvestrant-containing regimen is greater than 10%,as a historical comparison, when these patients receive combination fulvestrantand binimetinib therapy.
Patients with metastatic hormone receptor-positive HER2-negative breast cancers with a non-functional mutation in the NF1 gene.
95
ComboMATCH EAY191-N2 & N4 Study Overview by Drs. O'Cearbhaill and Westin
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.